<DOC>
	<DOCNO>NCT02034851</DOCNO>
	<brief_summary>Hypothesis : Administration corticoid ( dexamethasone ) together conventional antibiotherapy acute phase febrile urinary tract infection could reduce risk renal scar 6 month primo-infection . Primary objective : To evaluate reduction incidence renal scar 6 month acute pyelonephritis control group ( conventional therapy plus placebo ) intervention group ( conventional therapy plus dexamethasone . Design : Multicentre randomize clinical trial , placebo control , include child 2 month 14 year acute pyelonephritis proven acute phase DMSA ( dimethylsuccinic acid ) . A total 180 child parallel group ( intervention placebo ) include .</brief_summary>
	<brief_title>Dexamethasone Administration 1st Episode Febrile Urinary Tract Infection</brief_title>
	<detailed_description>The urinary tract infection ( UTI ) one common bacterial infection child . These infection group clinically asymptomatic bacteriuria , cystitis ( low urinary tract infection ) acute pyelonephritis ( APN ) infection reach upper urinary tract . This classification great clinical relevance cystitis usually benign condition without complication , APN associate increase risk kidney damage , acquire renal scarring . Renal scar consequence inflammatory immune response trigger eradicate bacteria involve UTI . Parenchymal infection solve , number poorly understood factor may perpetuate inflammation would promote formation scar nephritis . One relevant factor involve renal scarring development production inflammatory mediator ( complement protein , bactericidal peptide , cytokine IL6 IL8 , chemokines , adhesion molecule defensins ) . Thus , obvious think use anti-inflammatory drug may prevent release mediator development permanent kidney damage . Intervention : two parallel group receive conventional therapy plus : 1. dexamethasone : 0'30 mg per kg every 12 hour 3 day . 2. placebo ( physiological saline ) dose regimen . Centralized lecture late DMSA 6 month pyelonephritis episode perform . Renal scar presence grade report .</detailed_description>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Pyelonephritis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Those child 2 month 14 year provable acute pyelonephritis fulfill hospitalization criterion define Spanish Clinical practice guide . Briefly : age 3 month . general affectation , toxic appearance . vomit oral intolerance . dehydration , bad peripheric perfusion . intermedia situation include : 1. high fever ( &gt; 38.5 Celsius ) 36 month old child . 2. unusual germ risk factor . 3. family history vesicoureteral reflux . 4. recurrent febrile urinary infection . With absence previous renal scarring objectivated DMSA . 5. high elevation acute phase reactant . eligible patient fulfill hospitalization criterion . patient procalcitonin 0.05 ng per ml . patient previous uropathy renal scarring patient allergic dexamethasone . endocrinologic disease . history cancer . serious illness . immunosuppressor treatment . previous treatment corticoid ( continuous oral parenteral treatment ) last 2 month . patient include study present pyelonephritis acute phase DMSA evaluation exclude . patient include study suffer second pyelonephritis episode follow 6 month ( second DMSA evaluation ) exclude primary output analysis .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Acute pyelonephritis</keyword>
	<keyword>Renal scarring</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Children</keyword>
	<keyword>Corticoids</keyword>
	<keyword>Complementary treatment</keyword>
	<keyword>Prevention strategy</keyword>
</DOC>